Skip to Content
Merck
CN

75517

Orphenadrine hydrochloride

≥98.0% (AT)

Synonym(s):

β-Dimethylaminoethyl 2-methylbenzhydryl ether hydrochloride, N,N-Dimethyl-2-(2-methylbenzhydryloxy)ethylamine hydrochloride, o-Methyldiphenhydramine hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H23NO · HCl
CAS Number:
341-69-5
Molecular Weight:
305.84
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
57652570
EC Number:
206-435-4
Beilstein/REAXYS Number:
3745818
MDL number:
MFCD00012480

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Orphenadrine hydrochloride, ≥98.0% (AT)

InChI key

UQZKYYIKWZOKKD-UHFFFAOYSA-N

InChI

1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H

SMILES string

Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C

description

Drug Control: Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet.

assay

≥98.0% (AT)

form

powder

drug control

Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet

mp

160-164 °C

functional group

amine
ether
phenyl

Quality Level

100

Gene Information

human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444), HRH1(3269), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335), SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Muscarinic receptor antagonist; H1 histamine receptor antagonist; muscle relaxant. Orphenadrine has also been reported to inhibit the noradrenergic transporter and to block the NMDA receptor ion channel.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK2674
BCBS5264V
BCBM3941V
BCBH4323V
BCBB3303V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pål Gjerden et al.
British journal of clinical pharmacology, 68(2), 238-242 (2009-08-22)
Extrapyramidal side-effects induced by antipsychotic drugs are treated with dose reduction or substitution with another antipsychotic drug or by the addition of anticholinergic antiparkinson agents. The withdrawal of orphenadrine from the Norwegian market provided a possibility to investigate to what
Effect of warnings in a medical journal on the use of orphenadrine.
Pål Gjerden et al.
Journal of evaluation in clinical practice, 14(4), 615-617 (2008-05-09)
Yan-Chiao Mao et al.
Human & experimental toxicology, 29(11), 961-963 (2010-03-05)
Intoxication by orphenadrine is uncommon. The clinical features consist of both central and peripheral anticholinergic effects. Ingestion of 2 to 3 g orphenadrine in an adult has been associated with fatality. A 46-year-old female was brought to our emergency department
Pål Gjerden et al.
British journal of clinical pharmacology, 67(2), 228-233 (2008-12-20)
Anticholinergic antiparkinson drugs are used to ameliorate extrapyramidal symptoms caused by either Parkinson's disease or antipsychotic drugs, but their use in the treatment of Parkinson's disease is assumed to be in decline. Patients with psychotic conditions have a high prevalence
Hans Gombotz et al.
Wiener medizinische Wochenschrift (1946), 160(19-20), 526-534 (2010-10-05)
Multimodal pain management combines analgesics to improve analgesia and reduce side effects. This study investigates the fixed combination of diclophenac and orphenadrin (Neodolpasse(®) Infusion Solution) in patients after unilateral total hip arthroplasty (THA). This prospective, randomized, double-blind, placebo-controlled, multi-centre clinical
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service